Aggressive B-Cell Lymphomas

Similar documents
Aggressive B-cell Lymphomas

Aggressive B cell Lymphomas

Small B-cell (Histologically Low Grade) Lymphoma

Aggressive B cell Lymphomas

Differential diagnosis of hematolymphoid tumors composed of medium-sized cells. Brian Skinnider B.C. Cancer Agency, Vancouver General Hospital

Aggressive B-cell Lymphoma 2013

High grade B-cell lymphomas (HGBL): Altered terminology in the 2016 WHO Classification (Update of the 4 th Edition) and practical issues Xiao-Qiu Li,

Pathology of aggressive lymphomas

Aggressive B-cell lymphomas and gene expression profiling towards individualized therapy?

Defined lymphoma entities in the current WHO classification

Pathology of aggressive lymphomas

Update on the Classification of Aggressive B-cell Lymphomas and Hodgkin Lymphoma

EQA SCHEME CIRCULATION 33 EDUCATIONAL SLIDES DR GRAEME SMITH MONKLANDS DGH

Aggressive B-cell Lymphomas Updated WHO classification Elias Campo

Non-Hodgkin s Lymphomas Version

Immunopathology of Lymphoma

NEW ENTITIES IN AGGRESSIVE B CELL LYMPHOMA. Joon Seong Park, M.D. Dept. of Hematology-Oncology Ajou University School of Medicine

Hepatic Lymphoma Diagnosis An Algorithmic Approach

HIGH GRADE B-CELL LYMPHOMA DAVID NOLTE, MD (PGY-2) HUSSAM AL-KATEB, PHD, FACMG DEBORAH FUCHS, MD

The next lymphoma classification Luca Mazzucchelli Istituto cantonale di patologia, Locarno

Immunohistochemical classification of haematolymphoid tumours. Stephen Hamilton-Dutoit Institute of Pathology Aarhus University Hospital

Diffuse large B-cell lymphoma (DLBCL) is one of the

Lymphoma Update: Lymphoma Update: What s Likely to be New in the New WHO. Patrick Treseler, MD, PhD University of California San Francisco

7 Omar Abu Reesh. Dr. Ahmad Mansour Dr. Ahmad Mansour

Lymphoma/CLL 101: Know your Subtype. Dr. David Macdonald Hematologist, The Ottawa Hospital

Many of the hematolymphoid disorders are derived

IX. Is it only about MYC? How to approach the diagnosis of diffuse large B-cell lymphomas

Pearls and pitfalls in interpretation of lymphoid lesions in needle biopsies

DETERMINATION OF A LYMPHOID PROCESS

3/23/2017. Disclosure of Relevant Financial Relationships. Pitfalls in Immunohistochemistry in Hematopathology: CD20 and CD3 Can Let Me Down?!

WHO 4th ED Classification of Mature B-cell Neoplasms

Classification! Immunohistochemical classification of haematolymphoid tumours. Malignant lymphoproliferative diseases

Recent advances in the genetics & biology of lymphoma

From Morphology to Molecular Pathology: A Practical Approach for Cytopathologists Part 1-Cytomorphology. Songlin Zhang, MD, PhD LSUHSC-Shreveport

Classifications of lymphomas

Case year old male with abdominal lymphadenopathy Treated with 8 cycles of R-CHOP One year later B-symptoms and progressive disease

Low-grade B-cell lymphoma

Gray Zones and Double Hits Distinguishing True Burkitt Lymphoma from Other High-Grade B-NHLs Burkitt Lymphoma Burkitt-Like Lymphoma DLBCL Patrick Tres

LYMPHOMAS an overview of some subtypes of NHLs

Diffuse large B-cell lymphomas. G. Verhoef, MD, PhD University Hospital Leuven BHS, March 9, 2013

Diagnostic Molecular Pathology of Lymphoid Neoplasms

Conflict of Interest Disclosure Form NAME :James O. Armitage, M.D AFFILIATION: University of Nebraska Medical Center

Non-Hodgkin lymphomas (NHLs) Hodgkin lymphoma )HL)

Incidence. Bimodal age incidence 15-40, >55 years Childhood form (0-14) more common in developing countries M:F=1.5:1; in all subtypes except NS

Approach to Core Biopsy Specimens

Lymph node cytopathology : A practical approach to lymphoproliferative disorders

B Cell Lymphoma: Aggressive

Large cell immunoblastic Diffuse histiocytic (DHL) Lymphoblastic lymphoma Diffuse lymphoblastic Small non cleaved cell Burkitt s Non- Burkitt s

Aggressive NHL and Hodgkin Lymphoma. Dr. Carolyn Faught November 10, 2017

Use of MYC, BCL2 and BCL6 FISH for investigations of high grade B cell lymphoma

WHO UPDATE ON LYMPHOMAS. Dr Priya Mary Jacob Asst Professor, Pathology.

Lymphoma: The Basics. Dr. Douglas Stewart

9/28/2017. Follicular Lymphoma and Nodal Marginal Zone Lymphoma. Follicular Lymphoma Definition. Low-Grade B-Cell Lymphomas in WHO Classification

HODGKIN LYMPHOMA DR. ALEJANDRA ZARATE OSORNO HOSPITAL ESPAÑOL DE MEXICO

Common Problem Areas. WHO Classification. Defines separate diseases (entities) with their CLINICAL AGGRESSIVENESS LOW GRADE / HIGH GRADE

Diffuse Large B-Cell Lymphoma (DLBCL)

Burkitt lymphoma. Sporadic Endemic in Africa associated with EBV Translocations involving MYC gene on chromosome 8

Methods used to diagnose lymphomas

Commentary on the WHO Classification of Tumors of Lymphoid Tissues (2008): Aggressive B-cell Lymphomas

10/31/2017. Immunodeficiencies. Outline. Discuss EBV. Non-destructive Polymorphic Monomorphic Therapies Challenges

2010 Hematopoietic and Lymphoid ICD-O Codes - Alphabetical List THIS TABLE REPLACES ALL ICD-O-3 Codes

2012 Hematopoietic and Lymphoid ICD-O Codes - Numerical List THIS TABLE REPLACES ALL ICD-O-3 Codes

LINFOMA B (INCLASIFICABLE) CON RASGOS INTERMEDIOS ENTRE LINFOMA DE BURKITT Y LINFOMA B DIFUSO DE CÉLULAS GRANDES.

FOLLICULARITY in LYMPHOMA

Clinical Policy: Bendamustine (Bendeka, Treanda) Reference Number: PA.CP.PHAR.307

Aggressive Lymphomas - Current. Dr Kevin Imrie Physician-in-Chief, Sunnybrook Health Sciences Centre

Most reviews on diffuse large B-cell lymphoma

Mediastinal B-cell Lymphomas

Anaplastic Large Cell Lymphoma (of T cell lineage)

Contents. vii. Preface... Acknowledgments... v xiii

11/2/2017. Immunodeficiencies. Joo Y. Song, MD Assistant Professor of Clinical Pathology. I have no financial disclosures.

VENTANA hematopathology solutions. Deliver diagnostic confidence

3/2/2010. Case 1. Clinical History. Infectious Disease Pathology Specialty Conference Case 1

Low-Grade B-Cell Lymphomas in WHO Classification. Follicular Lymphoma Definition. Follicular Lymphoma Clinical Features 11/7/2017 DISCLOSURES

MANAGEMENT OF LYMPHOMAS

Infectious Disease Pathology Specialty Conference Case 1

Prevalent lymphomas in Africa

Does the proliferation fraction help identify mature B cell lymphomas with double- and triple-hit translocations?

T cell lymphoma diagnostics and differential diagnosis to Hodgkin lymphoma

DOUBLE-HIT AND TRIPLE-HIT LYMPHOMAS: NEW PERSPECTIVES FOR THEIR CLASSIFICATION

HIV ASSOCIATED LYMPHOMA. Dr N Rapiti

2012 by American Society of Hematology

VENTANA hematopathology solutions Comprehensive aids for detecting and subtyping

Aggressive lymphomas ASH Dr. A. Van Hoof A.Z. St.Jan, Brugge-Oostende AV

Methotrexate-associated Lymphoproliferative Disorders

Clinicopathologic features of 112 cases with mantle cell lymphoma

SH Comprehensive Molecular Profiling of an ALK-Negative, Anaplastic Large Cell Lymphoma with DUSP22 rearrangement

Lymphoma: What You Need to Know. Richard van der Jagt MD, FRCPC

Dispersed Cell Population & Lymphoglandular Bodies: Features of lymphoid aspirates FNA OF LYMPH NODES OF THE HEAD AND NECK

A Practical Guide To Diagnose B-Cell Lymphomas on FNAs. Nancy P. Caraway, M.D.

Case 3. Ann T. Moriarty,MD

Non-Hodgkin Lymphoma. Protocol applies to non-hodgkin lymphoma involving any organ system except the gastrointestinal tract.

HENATOLYMPHOID SYSTEM THIRD YEAR MEDICAL STUDENTS- UNIVERSITY OF JORDAN AHMAD T. MANSOUR, MD. Parts 2 and 3

Monoclonal B-cell Lymphocytosis

NON HODGKINS LYMPHOMA: AGGRESSIVE Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary)

5003 Immunohistochemistry in hematopathology, what's in, what's out, what's useful

PRECURSOR LYMHPOID NEOPLASMS. B lymphoblastic leukaemia/lymphoma T lymphoblastic leukaemia/lymphoma

Retrospective analysis of paediatric lymphomas at. Chris Hani Baragwanath Academic Hospital

Transcription:

Aggressive B-cell Lymphomas Aggressive B-Cell Lymphomas Stephen Hamilton Dutoit Institute of Pathology Aarhus Kommunehospital B-lymphoblastic lymphoma Diffuse large cell lymphoma, NOS T-cell / histiocyte-rich; primary CNS ; primary leg skin; EBV+ elderly Diffuse large B-cell lymphoma with chronic inflammation Lymphomatoid granulomatosis Primary mediastinal large B-cell lymphoma Intravascular large B-cell lymphoma ALK+ large B-cell lymphoma Plasmablastic lymphoma Large BCL, HHV8+ ex.castleman disease Primary effusion lymphoma Burkitt lymphoma B cell lymphoma, unclassifiable, Burkitt-like B cell lymphoma, unclassifiable, Hodgkin-like Mantle Cell Prolymphocytic Immunodeficiency associated lymphoma Post transplantation AIDS-associated Aggressive B-cell Lymphomas B-lymphoblastic lymphoma Diffuse large cell lymphoma, NOS T-cell / histiocyte-rich; primary CNS ; primary leg skin; EBV+ elderly Diffuse large B-cell lymphoma with chronic inflammation Lymphomatoid granulomatosis Primary mediastinal large B-cell lymphoma Intravascular large B-cell lymphoma ALK+ large B-cell lymphoma Plasmablastic lymphoma Large BCL, HHV8+ ex.castleman disease Primary effusion lymphoma Burkitt lymphoma B cell lymphoma, unclassifiable, Burkitt-like B cell lymphoma, unclassifiable, Hodgkin-like Mantle Cell Prolymphocytic Immunodeficiency associated lymphoma Post transplantation AIDS-associated Survival 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0 Large Cell Lymphomas: Overall Survival Log Rank Test: p<0.001 Anaplastic Large T-Cell Diffuse Large B-Cell Burkitt-like Peripheral T-Cell 0 1 2 3 4 5 6 7 8 9 Years Armitage et al, 1997 Danish Aggressive Lymphomas LYFO 2000 ca. 2100 patients DSB CB 78% IB 10% Burkitt 4% ALC 8% Precursor B-Cell B Lymphoblastic Lymphoma/Leukaemia Morphology lymphoblasts diffuse Immunology TdT + cytoplasmic mu -/+ CD19, 22, 79a + CD10 +/- CD34 +/- Genetics various Clinical leukaemic children > adults aggressive; curable CD45 CD10 1

Case 18 65-årig kvinde Hurtigt voksende lymfeknude på hals. Hun har haft feber nattesved. utilsigtet vægttab (ca. 9 kg. på 3 mdr.) Plasma LDH er forhøjet (840 U/L) Excision af 4 cm. stor lymfeknude (snit herfra). Case 18 - diagnoseforslag DLBCL 6 Mantlecelle lymfom - 5 Burkitts lymfom 1 Storcellet; obs ALC DDx: MCL, blastoid DLBL (B-cellNHL unclassified betweendlbcl & BL) Rule out PTL chl DSB Case 18 - diagnosis Diffuse Large B-cell Lymphoma Difuse large B-cell lymphoma Nodal 50% Extranodal 40% Both 10% BM involved 20% Most stage 1 or 2 DLBCL Presenting Features Enlarging mass in nodal or extranodal site Frequently symptomatic Occurs at all ages, more common after age 60 Extranodal sites: head & neck, GI, liver, skin, bone, bone marrow, others Presents both in limited and advanced stage Curative potential based on prognostic features DLBCL Presenting Features Enlarging mass in nodal or extranodal site Frequently symptomatic Occurs at all ages, more common after age 60 Extranodal sites: head & neck, GI, liver, skin, bone, bone marrow, others Presents in limited and advanced stage Curative potential based on prognostic features 2

CB IB B-ana Diffuse Large B-cell B Lymphoma Morphology large cells TCRBCL nucleoli diffuse Immunology surface Ig +/- cytoplasmic Ig -/+ CD19, 20, 22, 79a + CD30 -/+ CD20 CD38, CD138 pc CD5 10% CD10 40% bcl6 79% mum1 50% Genetics t(14;18) CD79 BCL-6 rearranged/mutated Clinical adult > children aggressive curable Large B-cell Lymphomas Morphologic Variants Centroblast-like Immunoblast-like > 90% IBs Centrocytoid Multilobated Anaplastic DLBCL: Centroblastic DLBCL: IB DLBCL: Centrocytoid DLBCL: Multilobated Diffuse large B-cell lymphoma: anaplastic 3

DLBCL: multilobated Basic IHC panel for lymphoma diagnosis CD45 CD20 CD79α (PAX-5) kappa/lambda CD3 CD5 CD30 CD43 CD163 (CD68) Bcl-2 Bcl-6 CD23 (CD21) Cyclin-D1 Ki-67 Immunophenotyping in DLBCL IHC panel for DLBCL diagnosis Add to basic panel: CD10 CD138 MUM1 DLBCL - Cell of Origin Large B-cell Lymphomas Molecular Variants 15 years ago! Germinal Centre B-cell Activated B-cell Nature. 2000 Feb 3;403(6769):503-11 4

DLBCL: cell of origin subtypes Molecular Profiling in B-Diffuse Large Cell Lymphoma Rosenwald et al. NEJM 346:1937, 2002 Overall Survival Nature. 2000 Feb 3;403(6769):503-11 DLBCL: Cell-of-Origin DLBCL - the HANS Classifier: Germinal centre (GC) & Activated B cell (ABC) types Can IHC be used as a surrogate for molecular profiling? Hans et al Blood. 2004;103(1):275-82 WHO Update 2016: Large B-cell lymphomas DLBCL: Cell-of-origin IHC classifiers Distinguishing GCB from non-gcb types will be now mandatory Any IHC algorithm accepted (state in report) many proposed no clear winner 5

Cell-of origin assay mrna molecular profiling (Nanostring) paraffin blocks Nanostring assay, paraffin Microarray assay, frozen Novel therapies in DLBCL based on of Cell of origin Several ongoing studies: Bortezomib in DLBCL (ABC) Ibrutinib in DLBCL (ABC) Etc. Large B-cell Lymphomas Subtypes T-cell-rich Primary CNS Mediastinal B-cell lymphoma Primary leg type EBV+ of elderly T-cell Rich Large B-cell Lymphoma T-cell Rich Large B-cell Lymphoma CD20 6

Diffuse Large B-cell Lymphoma Primary Mediastinal (Thymic) Large B-cell Lymphoma Rare variants: Mediastinal Intravascular Effusion younger patients + + sclerosis Hodgkin-like Primary Mediastinal (Thymic) Large B-cell Lymphoma Primary Mediastinal (Thymic) Large B-cell Lymphoma CD20 CD30 Ki-67 MUM-1 Cutaneous DLBCL, leg type Cutaneous DLBCL, leg type Elderly Often lower leg not always! Monomorphous large cell infiltrate CD20+ bcl2+ bcl6+ CD10- Better prognosis than DLBCL,nos 7

EBV-positive DLBCLs of the elderly Cutaneous Intravascular Large BCL CD20 EBER typical DLBCL > 50 yrs. EBVpos Asia?? ca. 5 % DLBCL weakened immune system? Intravascular Large B-cell Lymphoma Intravascular Large B-cell Lymphoma CD79 Plasmablastic B-celI Lymphoma Plasmablastic Lymphoma especially HIV+ especially oral CD138+ CD38+ MUM1+ Weak/neg for CD45 / CD20 / PAX5 8

Aggressive B-celI Lymphomas BL: Classical (30%) Burkitt lymphoma classical monomorphous, cohesive medium-sized blasts starry sky macrophages Burkitt Lymphoma Paraffin-FISH myc split probe Phenotype surface IgM + CD19, 20, 79a + CD10 +/- CD5, 23 - Ki-67 > 90% EBV positive 30% CD20 (B-cell) Genetics t(2;8), t(8;14), t(8;22) monoclonal c-myc rearranged TP53 inactivated (60%) Normal control lymph node t(8;14) positive Burkitt lymphoma Gray zone (bordeline) B-cell lymphomas Overlap between BL and DLBCL BL = Burkitt lymphoma BCLU = B-cell lymphoma unclassified, between DLBCL-BL DLBCL = diffuse large B-cell lymphoma DH = double hit lymphoma. These are seen in each group 9

Gray zone lymphomas new provisional WHO entities, 2008 Gray zone lymphomas new provisional WHO entities, 2008 B-cell lymphoma, unclassifiable intermediate between DLBCL and BL B-cell lymphoma, unclassifiable intermediate between DLBCL and BL B-cell lymphoma, unclassifiable intermediate between DLBCL and chl Less common lymphomas! B-cell lymphoma, intermediate between DLBCL and BL (BCLU, DLBCL/BL) BCLU DLBCL / BL Definition: B lineage lymphoma aggressive not common widespread disease, often extranodal some previously called BL-like overlapping features of DLBCL and BL: morphological immunophenotypic genetic mix of cells too big for BL, too small for DLBCL high proliferation rate with starry sky background morphology not typical for either DLBCL or BL Double-hit lymphomas Translocations - e.g. myc+ plus bcl-2+ or bcl-6+ DO NOT include Typical DLBCL with MYC rearrangement Typical BL without MYC rearrangement BCLU DLBCL / BL B-cell lymphoma, intermediate between DLBCL and BL (BCLU, DLBCL/BL) Starry sky background BL-like morphology BUT nuclei too big and irregular Immunophenotype: B-cell positive CD19 pos CD20 pos CD79 pos sig pos Often BL-like immunophenotype CD10 pos BCL6 pos BCL2 neg MUM1 neg/weak Includes BL-like morphology with strong BCL2 pos Test BCL2 pos cases for double-hit lymphoma with FISH Ki-67 index often very high e.g. >95% May also be lower than typical BL 10

BCLU DLBCL / BL BCLU, DLBCL-BL CD20 CD3 CD10 TdT Ki-67 BL-like immunophenotype (BCL2 neg ) Bcl-2 Male 30 years testis lymphoma starry sky background medium-sized blasts some nuclear irregularity BCLU, DLBCL-BL B-cell lymphoma, intermediate between DLBCL and BL (BCLU, DLBCL/BL) Genetics: IG genes rearranged 35+% - typical 8q24/MYC translocations BUT unlike BL, often not involving IG gene loci 15% have BCL2 translocation Often with BCL6 see double-hit lymphoma 100% proliferation (Ki-67) Bcl-2 expression Double-hit lymphoma BCL2 MYC Rearrangements of both BCL-2 & MYC Break apart probes show: 1 fusion signal 1 red arrow 1green arrow 11